Confirmation of BIK and SAMHD1 as Prostate Cancer Susceptibility Genes
- PMID: 40825105
- DOI: 10.1002/pros.70037
Confirmation of BIK and SAMHD1 as Prostate Cancer Susceptibility Genes
Abstract
Background: To independently assess data for recently reported genes-BIK, SAMHD1, FAM111A, and AOX1-in which rare variants have been associated with prostate cancer (PCa) risk and aggressiveness.
Methods: The study included 4448 PCa cases from Johns Hopkins School of Medicine and 103,221 population-based controls from the Genome Aggregation Database (gnomAD). Gene-based and variant-based association tests were performed within each major ancestry group using Fisher's exact test and Firth logistic regression. Bonferroni-corrected significance thresholds were applied to account for multiple testing.
Results and conclusion: In the NFE population, suggestive statistical evidence of association with PCa risk was found for two of the four genes, BIK and SAMHD1. The evidence was primarily driven by missense variants: BIK S87G and SAMHD1 Q465K and V112I. The effect sizes of these variants were stronger than, or comparable to, those of well-established PCa risk variants such as HOXB13 G84E and CHEK2 T367fs. A weak association signal was observed between AOX1 and PCa aggressiveness. Statistical power was limited for analyses in other ancestry groups, particularly for tests of PCa aggressiveness. Implication of BIK and SAMHD1 as PCa susceptibility genes represents a major breakthrough since the discovery of HOXB13 in 2012 and may have clinical utility for risk stratification and contribute to our understanding of the molecular etiology of PCa.
Keywords: AOX1; BIK; FAM111A; SAMHD1; germline; mutation; prostate cancer.
© 2025 The Author(s). The Prostate published by Wiley Periodicals LLC.
References
-
- E. V. Ivarsdottir, J. Gudmundsson, V. Tragante, et al., “Gene‐Based Burden Tests of Rare Germline Variants Identify Six Cancer Susceptibility Genes,” Nature Genetics 56, no. 11 (2024): 2422–2433.
-
- J. Mitchell, N. Camacho, P. Shea, et al., “Assessing the Contribution of Rare Protein‐Coding Germline Variants to Prostate Cancer Risk and Severity in 37,184 Cases,” Nature Communications 16, no. 1 (2025): 1779.
-
- E. Castro, C. Goh, D. Leongamornlert, et al., “Effect of BRCA Mutations on Metastatic Relapse and Cause‐Specific Survival After Radical Treatment for Localised Prostate Cancer,” European Urology 68, no. 2 (2015): 186–193.
-
- C. C. Pritchard, J. Mateo, M. F. Walsh, et al., “Inherited DNA‐Repair Gene Mutations in Men With Metastatic Prostate Cancer,” New England Journal of Medicine 375, no. 5 (2016): 443–453.
-
- R. Na, S. L. Zheng, M. Han, et al., “Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and Are Associated With Early Age at Death,” European Urology 71, no. 5 (2017): 740–747.
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
